Revised: 6 May 2019

Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research **Medicare study**

Rohit Bishnoi¹ Voung-Rock Hong² Chintan Shah¹ Azka Ali¹ William P. Skelton IV¹ | Jinhai Huo² | Nam H. Dang¹ | Long H. Dang¹

¹Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL

²Department of Health Services Research, Management and Policy, College of Public Health and Health Professions, University of Florida, Gainesville, FL

Correspondence

Jinhai Huo, 1225 Center Drive, HPNP 3111, PO Box 100195, Gainesville, FL 32610 Email: jhuo@ufl.edu

Nam H. Dang, PO Box 100278, 1600 SW Archer Rd, Gainesville, FL 32610. Email: nam.dang@medicine.ufl.edu

Long H. Dang, PO Box 100278, 1600 SW Archer Rd, Gainesville, FL 32610. Email: long.dang@ochsner.org

Abstract

Background: Dipeptidyl peptidase 4 (DPP4) is a cell surface protein that can act as a tumor suppressor or activator, depending upon the level of expression and interaction with the microenvironment and chemokines. DPP4 inhibitors are used to treat diabetes.

Methods: We conducted this Surveillance Epidemiology and Endpoint Research-Medicare database study to evaluate the role of DPP4 inhibitors on the overall survival (OS) of diabetic patients diagnosed with colorectal (CRC) and lung cancers.

Results: Diabetic patients with CRC or lung cancer who were treated with DPP4 inhibitors exhibited a statistically significant survival advantage (hazard ratio [HR] of 0.89; CI: 0.82-0.97, P = 0.007) that remained significant after controlling for all other confounders. When DPP4 inhibitors were used in combination of metformin which is known to suppress cancer, the survival advantage was even more pronounced (HR of 0.83; CI: 0.77-0.90, P < 0.0001). Data were then analyzed separately for two cancer types. In the CRC-only cohort, the use of DPP4 inhibitors alone had a positive trend but did not meet statistically significant threshold (HR of 0.87; CI: 0.75-1.00, P = 0.055), while the combined use of DPP4 inhibitors and metformin was associated with statistically significant survival advantage (HR of 0.77; CI: 0.67-0.89, P = 0.003). Similarly, for the lung cancer cohort, use of DPP4 alone was not found to be statistically significant (HR of 0.93; CI: 0.83-1.03, P = 0.153), whereas lung cancer patients treated with the combination of DPP4 inhibitors and metformin showed statistically significant survival advantage (HR of 0.88; CI: 0.80-0.97, P = 0.010). Conclusions: DPP4 inhibition in CRC and lung cancer is associated with improved

OS, which possibly may be due to the effect of DPP4 inhibition on immunoregulation of cancer.

Rohit Bishnoi and Young-Rock Hong are contributed equally.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited

© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

WILEY-

K E Y W O R D S CD26, colorectal cancer, DPP4 inhibitors, lung cancer, SEER-Medicare

1 INTRODUCTION

Dipeptidyl peptidase 4 (DPP4) inhibitors, also known as gliptins, are a class of oral hypoglycemic drugs that block the enzyme DPP4 and can be used to treat diabetes mellitus type 2 (DM-II). By inhibiting DPP4, these agents increase incretin levels to inhibit glucagon release and stimulate insulin release, thereby reducing serum glucose levels. The first drug in this class was sitagliptin, which was approved by the US Food and Drug Administration (FDA) in 2006 for use in DM-II. Since then, multiple agents in this class of drugs have been approved for this indication, and the use of this class of drug is on the rise.

Apart from the use of these drugs in the management of DM-II, the role of DPP4 inhibitors in cancer biology has been a topic of interest in many studies. DPP4, also known as cluster of differentiation 26 (CD26), is a cell membrane protein enzyme which cleaves dipeptides from various growth factors and chemokines resulting in their enhanced degradation.¹ DPP4/CD26 is widely expressed on different tissues as well as is present in serum and other body fluids. It plays an important role in tumor biology by acting as a tumor suppressor or activator depending upon the level of expression and its interaction with the microenvironment and selected chemokines.¹⁻³ In animal models, DPP4/CD26 expression has been shown to be of prognostic value and is a potential therapeutic target in various malignancies.⁴⁻⁷ Of note is that the first phase I clinical trial involving CD26-expressing cancers with an anti-CD26 monoclonal antibody was recently completed and reported prolonged disease stabilization in patients with mesothelioma with good drug tolerance.⁸

Barreira da Silva et al⁹ showed that in mice models with melanoma, DPP4 inhibition preserved the active form of chemokine CXCL10 which recruits T cells in tumor parenchyma. Their study also provided evidence that the use of a DPP4 inhibitor in combination with a programmed cell death protein 1 inhibitor and cytotoxic T lymphocyte-associated antigen-4 inhibitor enhances antitumor response to immunotherapy regimens. Similarly, Pereira et al showed that in mice models with melanoma, treatment with metformin or sitagliptin showed a significant reduction in the number of metastatic lung nodules. Importantly, the combination of metformin with sitagliptin showed a greater reduction in the number of metastatic lung nodules than treatment with metformin or sitagliptin alone.¹⁰ In the mouse xenograft model with papillary thyroid cancer, sitagliptin use was associated with reduced tumor growth, with the transforming growth factor- β signaling pathway being potentially involved.⁵ In contradiction to these findings, Wang et al¹¹ demonstrated in an in-vivo study that use of DPP4 inhibitors increased the risk of metastasis in colon, hepatic, lung, ovary, and melanoma cell lines.

Due to these in-vivo studies showing that DPP4/CD26 inhibition can either deter or facilitate tumor progression, we previously conducted a multi-institutional retrospective study involving patients with advanced airway and colorectal cancers (CRCs) who were being treated for diabetes with DPP4 inhibitors. Our study, which to our knowledge was the first study evaluating the role of DPP4 inhibition on cancers in human subjects, found statistically significant benefit in progression-free survival and a positive trend in overall survival (OS); however, this benefit in OS did not reach the level of statistical significance, likely due to the relatively small number of subjects included in the study.¹² As a follow-up and to further clarify the role of DPP4 inhibitors in human malignancies, we conducted a national database study in CRC and lung cancer.

2 | MATERIALS AND METHODS

2.1 | Databases

We utilized the Surveillance Epidemiology and Endpoint Research (SEER)-Medicare database for our study. The SEER program, supported by the National Cancer Institute, contains cancer patients' demographic and tumor characteristics for approximately 34% of the US population. The Medicare database, maintained by the Centers for Medicare and Medicaid Services, contains health care claims and payment information, for over 97% of the US population aged 65 years or older. We used this linked SEER and Medicare databases (SEER-Medicare), which capture detailed treatment information after cancer diagnosis from the Medicare insurance program along with individual patient level demographic and survival data from the SEER cancer registry program.

2.2 | Study population

We used International Classification of Diseases for Oncology, third edition (ICD-O-3) codes to identify patients who were diagnosed with colorectal and lung cancer between 2001 and 2013 from SEER 18.¹³ We excluded patients in whom cancer diagnosis was from autopsy or death certificates or without pathological confirmation. The study samples were restricted to those with continuous Medicare

		SEER-Medicare 2001-2013			
Step	Criteria	Inclusion	Exclusion		
1	Diagnosis of lung cancer between years 2001-2013	384085			
2	Excluded those younger than 65 at diagnosis	309182	74903		
3	Excluded if diagnosis was not pathologically confirmed	276118	33064		
4	Excluded if diagnosis came from either an autopsy or death certificate	275820	298		
5	Excluded if no continuous coverage through enrollment in Medicare Part A and B	245241	30579		
6	Excluded if enrolled in HMO coverage	166772	78469		
7	Excluded if no continuous enrollment in Medicare Part D	81620	85152		
8	Excluded if not diagnosed with diabetes prior to cancer	26858	54762		




FIGURE 1 This shows the criteria and the flowchart used to identify study cohort

Part A and Part B insurance coverage and no HMO coverage 12 months before and 12 months after a cancer diagnosis or until death. Cohort was then selected for patients who were diagnosed with diabetes prior to the diagnosis of cancer. Please refer to Figure 1 for details of cohort selection.

2.3 | Dependent and independent variables

Use of DPP4 inhibitors following cancer diagnosis was identified using a generic name and National Drug Codes in SEER-Medicare Part D file. DPP4 inhibitors included in the study were: alogliptin, linagliptin, saxagliptin, sitagliptin, and vildagliptin. We also used the same approach to identify the use of metformin. Patient demographic characteristics included the year of diagnosis, age, sex, race/ethnicity, marital status, census tract poverty rate, census region, urban/rural status. Patient's clinical information included cancer type, cancer stage, receipt of cancer treatment (such as surgery, chemotherapy, and radiation therapy), and comorbidity using Charlson comorbidity Index.^{14,15} This index is comprised of 14 different conditions, which include cardiac, renal, liver, neurologic, and dementia among others. The type of cancer treatment received within 1 year of cancer diagnosis was identified using both ICD (ninth revision) procedure codes and level II Healthcare Common Procedure Coding System: Current Procedural Terminology codes in the Medicare claims. We used the modified algorithm by Klabunde et al^{14,15} to calculate the Charlson Comorbidity Index.
 TABLE 1
 General demographics of the cohort by DPP4 inhibition

		DPP4				
Characteristic	Total	No	%	Yes	%	<i>P</i> -value
Demographics						
Year of diagnosis						< 0.0001
2007	2261	2214	8.8	47	2.6	
2008	4003	3858	15.4	145	8.1	
2009	4128	3962	15.8	166	9.3	
2010	3953	3718	14.8	235	13.2	
2011	3981	3651	14.6	330	18.5	
2012	4236	3801	15.2	435	24.4	
2013	4296	3868	15.4	428	24.0	
Age group						0.201
65-69	5301	4938	19.7	363	20.3	
70-74	6844	6367	25.4	477	26.7	
75-79	6156	5739	22.9	417	23.3	
80+	8557	8028	32.0	529	29.6	
Sex						0.018
Male	12 451	11 575	46.2	876	49.0	
Female	14 407	13 497	53.8	910	51.0	
Race/Ethnicity						< 0.0001
Non-Hispanic White	19 012	17 812	71	1200	67.2	
Non-Hispanic Black	3132	2975	11.9	157	8.8	
Hispanic	2462	2263	9.0	199	11.1	
Others	2252	2022	8.1	230	12.9	
Marital status						0.0006
Single	5930	5586	22.3	344	19.3	
Married	11 379	10 551	42.1	828	46.4	
Other (Sep/Div/Wid/ Unknown)	9549	8935	35.6	614	34.4	
Census poverty						0.058
0% to <5% poverty	4680	4335	17.3	345	19.3	
5% to <10%	6131	5736	22.9	395	22.1	
10%-20%	8098	7584	30.2	514	28.8	
20%-100%	7444	6956	27.7	488	27.3	
Unknown	505	461	1.8	44	2.5	
Census region						< 0.0001
West	9818	9072	36.2	746	41.8	
Northeast	6280	5841	23.3	439	24.6	
Midwest	3084	2952	11.8	132	7.4	
South	7676	7207	28.7	469	26.3	
Rural/urban status						0.085
Urban area	26 147	24 397	97.3	1750	98.0	
Rural area	711	675	2.7	36	2.0	

3921

-WILEY-

Cancer Medicine

(Continues)

TABLE 1 (Continued)

3922

		DPP4	DPP4				
Characteristic	Total	No	%	Yes	%	<i>P</i> -value	
Charlson Comorbid Index						<0.0001	
0	2471	2436	9.7	35	2.0		
1	8139	7623	30.4	516	28.9		
2	6381	5916	23.6	465	26.0		
3+	9867	9097	36.3	770	43.1		
Cancer type						0.105	
Colorectal cancer	11 657	10 849	43.3	808	45.2		
Lung cancer	15 201	14 223	56.7	978	54.8		
Stage						0.221	
Ι	5947	5543	22.1	404	22.6		
II	3444	3219	12.8	225	12.6		
III	6352	5927	23.6	425	23.8		
IV	8156	7592	30.3	564	31.6		
Unknown	2959	2791	11.1	168	9.4		
Surgery						0.355	
No	19 219	17 958	71.6	1261	70.6		
Yes	7639	7114	28.4	525	29.4		
Chemotherapy						0.0791	
No	21 470	20 071	80.1	1399	78.3		
Yes	5388	5001	19.9	387	21.7		
Radiotherapy						0.566	
No	24 472	22 838	91.1	1634	91.5		
Yes	2386	2234	8.9	152	8.5		

Abbreviation: DPP4, dipeptidyl peptidase 4.

2.4 | Study cohorts and statistical analysis

Metformin is another antidiabetic drug, which is widely prescribed and is probably the most common drug used for the treatment of DM-II. It is also is well-established fact that metformin has a role in tumor suppression and improving OS in multiple cancers, including colorectal and lung cancer.¹⁶⁻¹⁹ To avoid confounding by metformin use, we divided the study cohort into four groups for survival analysis. We classified patients into four groups with respect to use of DPP4 inhibitors and metformin: (a) not on either medication (not DPP4 inhibitors nor metformin; reference group), (b) on metformin only, (c) on DPP4 inhibitors only, and (d) on DPP4 inhibitors with metformin (combination group). We used the Cox Proportional Hazards survival model to assess the outcome of the four groups, controlling for patient's demographic and clinical characteristics. Reference group in our study included diabetic patients with CRC or lung cancer and not on metformin or DPP4 inhibitors.

Bivariate analyses compared baseline characteristics between DPP4 inhibitors users and nonusers using Pearson chisquare tests. The survival time was defined as from the date of cancer diagnosis until date of death or loss of follow-up. The criterion for statistical significance was a P < 0.05. All statistical analyses were conducted using SAS software (version 9.4; SAS Institute, Cary, NC, USA). The University of Florida institutional review board approved this study.

3 | RESULTS

A total of 26 858 numbers of patients were found to have the diagnosis of diabetes and developed either CRC or Lung cancer. Of 26 858 patients, 11 657 had CRC while 15 201 had lung cancer. Of these, 1786 patients were on DPP4 inhibitors for DM-II. Table 1 shows general demographic information about the cohort. As seen in this table, use of DPP4 inhibitors has been increasing since the time of FDA approval in 2006 (2.6% in 2007 to 24% in 2013). Of these 1786 patients, 1011

Cancer Medicine

WILEY

were on DPP4 inhibitors in combination metformin, and 775 were only on DPP4 inhibitors.

Our analysis found that use of DPP4 inhibitors by itself or in combination with metformin improved OS, which was statistically significant. Taking the entire study cohorts of CRC and lung cancers together, patients using DPP4 inhibitors only (n = 775) had hazard ratio (HR) of 0.89 (95% CI: 0.82-0.97, P = 0.007) while the patients with combined use of DPP4 inhibitors and metformin (n = 1011) showed HR 0.83 (95% CI: 0.77-0.90, P < 0.0001).

The analysis was further performed for CRC and lung cancer cohorts independently. In CRC cohort, patients using DPP4 inhibitor only (n = 356) had HR of 0.87 (95% CI: 0.75-1.00, P = 0.055) while patients with combined use of DPP4 inhibitors and metformin (n = 452) showed HR of 0.77 (95% CI: 0.67-0.89, P = 0.003). In lung cancer patients, DPP4

inhibitor only group (n = 419) showed HR of 0.93 (95% CI: 0.83-1.03, P = 0.153) while the group with combined use of DPP4 inhibitors and metformin (n = 559) showed HR of 0.88 (95% CI: 0.80-0.97, P = 0.010).

After primary analysis, we performed further analysis to identify any other demographic, treatment, or cancerrelated variable that was significant in patients on DPP4 inhibitors. In this analysis, we excluded patients who were on metformin to remove this confounding variable. Figure 2 represents a combined cohort of CRC plus Lung cancer patients (n = 17 517), Figure 3 shows analysis for CRC patients (n = 7573), and Figure 4 shows analysis for lung cancer patients (n = 9944). In this analysis, we saw a persistent and significant HR for females and White people in the combined cohort of lung cancer and CRC patients, as well as in lung cancer patients only and CRC patients only cohorts. We

Insulin Yes No	N (obs) 3640 13877				Hazard Ratios 0.94 (0.81-1.11) 0.87 (0.78-0.96)	P-value 0.467 0.006
Sulfonylurea Yes No	3809 13708	⊢ ∎ 1			0.97 (0.85-1.11) 0.83 (0.74-0.94)	0.631 0.002
Chemotherapy Yes No	3229 14288	⊢∎⊣			1.07 (0.88-1.31) 0.86 (0.78-0.94)	0.486 0.002
Radiotherapy Yes No	1496 16021	,	•	-	1.28 (0.96-1.70) 0.86 (0.79-0.95)	0.095 0.002
Age Group 65-69 70-74 75-79 80+	3089 4133 4009 6286		-		0.86 (0.69-1.08) 0.86 (0.72-1.04) 1.04 (0.87-1.24) 0.82 (0.72-0.94)	0.188 0.127 0.688 0.005
Sex Male Female	7995 9522	⊧ -₩- -1			0.89 (0.79-1.01) 0.87 (0.78-0.98)	0.079 0.027
Race/Ethnicity NH White NH Black Hispanic Others	12479 2200 1402 1436		.		0.84 (0.75-0.93) 0.83 (0.63-1.09) 1.27 (1.00-1.62) 0.96 (0.71-1.30)	0.001 0.172 0.048 0.799
Charlson Index 0 1 2 3+	2011 4656 3743 7107				1.13 (0.62-2.07) 0.90 (0.73-1.11) 0.80 (0.65-0.98) 0.91 (0.82-1.02)	0.695 0.344 0.030 0.098
Stage I II III IV Unknown	3966 2242 4051 5214 2044				0.88 (0.72-1.08) 0.80 (0.60-1.05) 0.94 (0.78-1.12) 0.91 (0.79-1.04) 0.83 (0.63-1.09)	0.233 0.110 0.480 0.171 0.182
	0.4	0.7 1.0	1.3 1.6	1.9	2.2	
	← Favoi	urs DDP4 inhibitors	Favours	refernce gro	oup→	

FIGURE 2 HR of patients using DPP4 inhibitor only (n = 775) in interaction with other variables in the study population after excluding patients treated with metformin (n = 1751). DPP4, dipeptidyl peptidase 4; HR, hazard ratio

WILEY_Cancer Medicine

did find other significant variables, but these findings were not consistent throughout the groups. Please see the attached figures for other variables.

4 | DISCUSSION

Our study included two groups of cancers, CRC and lung cancers, which have a different clinical course. We included the same group of cancers as we included in our initial retrospective study.¹² With a larger sample size, our present study showed statistically significant HR in the combined cohort of CRC and lung cancer patients. Results showed that DPP4 inhibitor use was associated with an improved OS with a statistically significant HR. This effect was seen with DPP4 inhibitors use, either by itself (HR 0.89) or in combination with metformin (HR 0.83). On analysis of individual cohorts of CRC and lung cancers, results were still statistically significant for the combined use of DPP4 inhibitors and metformin in CRC (HR 0.77) as well as for lung cancer (HR 0.88).

However, the results did not meet statistically significant threshold for isolated use of DPP4 inhibitors in separate

cohorts of lung and CRC, which we believe is due to smaller sample size. Results were still very encouraging for the CRC cohort with patients treated with DPP4 inhibitors showing a positive trend in improved survival but not meeting statistically significant threshold with HR of 0.87 (95% CI: 0.75-1.00, P = 0.055). In patients with lung cancer, similar analysis showed HR of 0.93 (95% CI 0.83-1.03, P = 0.153), which was not significant. This difference again can be related to the smaller sample size as well as the different clinical course of these two different diseases. We performed detailed analysis for different variables and their interaction with DPP4 inhibitor use as compared to the reference group. Although we did find some subgroups that showed significant benefit from DPP4 inhibitor use such as White race and female gender, the clinical significance of these findings and the underlying mechanism are unclear. It will be interesting to see if these findings can be replicated with larger sample size or prospective trials.

Metformin, which is known to have an adjunctive protective role in malignancy, was again found to be statistically significant in a combined cohort of CRC and lung, as well as separately in each CRC and lung cancer cohort.

Insulin	N (obs		Hazard Ratios	P-value
Yes	1720) -	0.86 (0.67-1.10)	0.237
No	5853			
Sulfonylurea	0000		0.84 (0.70-1.01)	0.061
Yes	1740		0.90 (0.72-1.12)	0.338
No	5833		0.82 (0.67-0.99)	
Chemotherapy	0000		0.82 (0.87-0.99)	0.040
Yes	1094		0.72 (0.49-1.07)	0 107
No	6479		0.72 (0.49-1.07)	0.107 0.060
Radiotherapy	0475	-	0.86 (0.74-1.01)	0.060
Yes	244		1.96 (0.96-3.97)	0.064
No	7329		0.83 (0.72-0.96)	0.004
Age Group	1525		0.83 (0.72-0.96)	0.015
65-69	1089		0 00 (0 50 1 20)	0.249
70-74	1580		0.80 (0.50-1.28) 0.83 (0.59-1.17)	0.348 0.299
75-79	1584			
80+	3320		0.75 (0.53-1.07)	0.111 0.173
Sex	0020		0.87 (0.71-1.06)	0.173
Male	3220	⊢ ■	0.94 (0.75-1.17)	0.567
Female	4353		0.80 (0.66-0.97)	0.023
Race/Ethnicity	4000		0.80 (0.80-0.97)	0.023
NH White	5206	H H -1	0.82 (0.69-0.98)	0.028
NH Black	995		0.77 (0.49-1.21)	0.255
Hispanic	658		1.08 (0.71-1.63)	0.233
Others	714		0.89 (0.53-1.49)	0.656
Charlson Index	/ 14		0.69 (0.55-1.49)	0.050
0	971		0.18 (0.03-1.34)	0.094
1	2180		0.91 (0.65-1.27)	0.569
2	1555		0.80 (0.58-1.11)	0.188
3+	2867		0.85 (0.71-1.03)	0.094
Stage	2007		0.05 (0.7 1-1.05)	0.094
l	1722		0.69 (0.49-0.99)	0.041
II	1861		0.69 (0.50-0.94)	0.041
 III	1622		0.89 (0.66-1.20)	0.448
IV	1161		1.15 (0.84-1.57)	0.386
Unknown	1207		0.71 (0.48-1.05)	0.088
Histology	1201		0.71 (0.46-1.05)	0.000
Adenocarcinoma	7110		0.85 (0.73-0.98)	0.029
Others	118		0.48 (0.11-2.12)	0.331
Location			0.40 (0.11-2.12)	0.001
Right	3255		0.83 (0.67-1.03)	0.092
Left	2271		0.93 (0.72-1.21)	0.604
Other	2047		0.79 (0.58-1.10)	0.004
		· · · · · · · · · · · · · · · · · · ·	0.10 (0.00-1.10)	0.120
		0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0		
		0.0 0.0 1.0 1.0 2.0 2.0 0.0 0.0 4.0		

← Favours DDP4 inhibitors

rs Favours refernce group→

FIGURE 3 HR of patients using DPP4 inhibitor only (n = 356) in interaction with other variables in CRC cohort (n = 7573). DPP4, dipeptidyl peptidase 4; HR, hazard ratio

FIGURE 4 HR of patients using DPP4 inhibitor only (n = 419) in interaction with other variables in Lung cancer cohort (n = 9944). DPP4, dipeptidyl peptidase 4; HR, hazard ratio Insulin (N = 0824) No N (obs) 8024 He Hazard Ratios 0.97 (0.79-1.19) P-value 0.97 (0.79-1.19) Yes 2069	BISHNOI ET AL.				Cancer Medicine		Y 3925
DPP4 inhibitor only (n = 419) in interaction with other variables in Lung cancer cohort (n = 9944). DP4, dipeptidyl peptidase 4; HR, hazard ratio No 8024 Pes 2069 No 7875 No 787 No 7875 No 7875 No 787 No 77 No 77 No 80 00 12 No	FIGURE 4 HR of patients using						
with other variables in Lung cancer cohort (n = 9944). DPP4, dipeptidyl peptidase 4; HR, hazard ratio HR, hazard rati	DPP4 inhibitor only $(n = 419)$ in interaction			⊢∎⊨⊣			
(n = 9944). DPP4, dipeptidyl peptidase 4; Yes 2069 1.01 (0.86-1.20) 0.891 HR, hazard ratio Yes 2135 0.86 (0.75-1.00) 0.043 Yes 2135 0.87 (0.77-0.98) 0.025 Radiotherapy 1.22 (0.88-1.69) 0.228 No 7809 0.90 (0.80-1.01) 0.075 Age Group 65-69 2000 0.90 (0.80-1.01) 0.253 65-69 2000 1.14 (0.93-1.41) 0.294 75-79 2425 0.81 (0.67-0.98) 0.032 80+ 2966 0.81 (0.67-0.98) 0.032 Sex Male 4775 0.86 (0.75-0.98) 0.014 NH White 7273 0.86 (0.75-0.98) 0.014 NH White 7273 0.86 (0.75-0.98) 0.014 NH White 7273 0.99 (0.64-1.20) 0.525 Hispanic 744 0.99 (0.67-1.41) 0.872 NH White 7273 0.99 (0.67-1.41) 0.872 NH White 727 0.99 (0.67-1.41) 0.872 NH White 722 0.97 (0.67-1.41) 0.872 <td></td> <td></td> <td>8024</td> <td>H</td> <td></td> <td>0.90 (0.79-1.02)</td> <td>0.097</td>			8024	H		0.90 (0.79-1.02)	0.097
III = 9944). DPP4, dipending periodase 4; No 7875 0.06 (0.75-1.00) 0.043 HR, hazard ratio Chemotherapy Yes 2135 0.86 (0.75-1.00) 0.043 No 7809 0.87 (0.77-0.98) 0.025 Radiotherapy Yes 1252 0.90 (0.80-1.01) 0.075 No 8892 0.90 (0.80-1.01) 0.075 Age Group 65-69 2000 1.12 (0.88-1.69) 0.228 No 8892 0.90 (0.80-1.01) 0.075 Age Group 65-69 2000 1.14 (0.93-1.41) 0.199 80+ 2966 0.81 (0.67-0.98) 0.032 Sex Male 4775 0.94 (0.81-1.10) 0.429 Race/Ethnicity 0.94 (0.81-1.10) 0.429 NH White 727 0.94 (0.81-1.10) 0.429 Race/Ethnicity 0.97 (0.67-1.41) 0.87 (0.77-0.98) 0.019 NH White 722 0.97 (0.67-1.41) 0.87 (0.77-0.98) 0.019 NH White 723 0.97 (0.67-1.41) 0.87 (0.77-0.98) 0.019 NH White 724 0.	with other variables in Lung cancer cohort						
HR, hazard ratio No 7875 0.86 (0.75-1.00) 0.043 HR, hazard ratio Chemotherapy Yes 2135 1.25 (0.99-1.58) 0.060 No 7809 0.87 (0.77-0.98) 0.025 0.075 0.90 (0.80-1.01) 0.075 Radiotherapy Yes 125 1.22 (0.88-1.69) 0.228 0.90 (0.80-1.01) 0.075 Age Group 65-69 2000 1.25 (0.91-1.11) 0.253 70-74 2553 1.14 (0.93-1.41) 0.199 80+ 2966 1.14 (0.93-1.41) 0.199 0.80 (0.77-0.98) 0.032 Sex Male 4775 0.81 (0.67-0.98) 0.032 Male 4775 0.91 (0.78-1.06) 0.219 Race/Ethnicity 0.91 (0.78-1.06) 0.219 NH White 7273 0.96 (0.64-1.26) 0.525 Hispanic 744 0.97 (0.67-1.41) 0.872 Charison Index 0.97 (0.67-1.41) 0.872 0.078 1 2476 0.97 (0.67-1.41) 0.872 Charison Index 0.90 (0.69-1.18) 0.451 0.95 (0.83-1.09) 0.451 <td>(n = 9944), DPP4, dipeptidyl peptidase 4;</td> <td></td> <td></td> <td>⊢∎∎⊣</td> <td></td> <td>1.01 (0.86-1.20)</td> <td>0.891</td>	(n = 9944), DPP4, dipeptidyl peptidase 4;			⊢∎∎⊣		1.01 (0.86-1.20)	0.891
Yes 2135 1.25 (0.99.1.58) 0.060 Radiotherapy Yes 1.25 (0.99.1.58) 0.025 No 8692 0.87 (0.77-0.98) 0.228 No 8692 0.90 (0.80-1.01) 0.075 Age Group 65-69 2000 0.86 (0.66-1.11) 0.223 65-69 2000 0.89 (0.71-1.11) 0.294 70-74 2553 0.81 (0.67-0.98) 0.032 70-74 2553 0.81 (0.67-0.98) 0.032 Sex 0.81 (0.67-0.98) 0.032 Male 4775 0.91 (0.78-1.06) 0.219 Race/Ethnicity 0.91 (0.78-1.06) 0.219 NH White 7273 0.97 (0.67-1.41) 0.872 NH White 722 0.97 (0.67-1.41) 0.872 Others 722 0.97 (0.67-1.41) 0.872 Others 722 0.97 (0.67-1.41) 0.872 1 2476 1.17 (1.08-1.98) 0.014 Others 722 0.97 (0.67-1.41) 0.872 1 2478 0.95 (0.83-1.08) 0.451			7875	H - H		0.86 (0.75-1.00)	0.043
No 7809 0.87 (0.77.0.98) 0.025 Radiotherapy Yes 1252 1.22 (0.88-1.69) 0.228 No 8692 0.90 (0.80-1.01) 0.075 Age Group 0.86 (0.66-1.11) 0.294 65-69 2000 1.14 (0.93-1.41) 0.199 70-74 2553 1.14 (0.33-1.41) 0.199 80+ 2966 0.81 (0.67-0.98) 0.032 Sex 0.81 (0.67-0.98) 0.032 Male 4775 0.91 (0.78-1.66) 0.219 Race/Ethnicity 0.94 (0.81-1.10) 0.429 NH White 7273 0.99 (0.64-1.26) 0.525 Hispanic 744 0.97 (0.67-1.41) 0.872 Others 722 0.97 (0.67-1.41) 0.872 Others </td <td>HR, nazard ratio</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	HR, nazard ratio						
Radiotherapy Yes 1252 1.22 (0.88-1.69) 0.228 No 8692 0.90 (0.80-1.01) 0.075 Age Group 65-69 2000 1.22 (0.88-1.69) 0.228 65-774 2553 0.89 (0.71-1.11) 0.294 70-74 2553 1.14 (0.33-1.41) 0.199 80+ 2966 0.81 (0.67-0.98) 0.032 Sex 0.91 (0.78-1.06) 0.219 Race/Ethnicity 0.94 (0.81-1.10) 0.429 NH White 7273 0.86 (0.75-0.98) 0.019 NH Black 1205 1.47 (1.08-1.98) 0.219 NH White 722 0.90 (0.64-1.26) 0.525 Hispanic 744 1.47 (1.08-1.98) 0.014 O 1040 1.79 (0.94-3.42) 0.078 Q 1040 1.79 (0.94-3.42) 0.078 1 2476 0.99 (0.69-1.18) 0.457 2 2188 0.81 (0.62-1.06) 0.125 3+ 4240 1.14 (0.94-3.49) 0.075 1 244 1.81 (0.94-3.49) 0.075					-	1.25 (0.99-1.58)	0.060
Yes 1252 1.22 (0.88-1.69) 0.228 No 8692 0.90 (0.80-1.01) 0.075 Age Group 65-69 2000 0.86 (0.66-1.11) 0.253 70-74 2553 1.14 (0.93-1.41) 0.199 80+ 2966 0.81 (0.67-0.98) 0.032 Sex 0.81 (0.67-0.98) 0.032 Male 4775 1.14 (0.93-1.41) 0.199 Race/Ethnicity 0.91 (0.78-1.06) 0.219 NH Black 1205 0.94 (0.81-1.10) 0.429 Race/Ethnicity 0.90 (0.64-1.26) 0.525 Hispanic 744 1.47 (1.08-1.98) 0.019 NH Black 1205 9.07 (0.67-1.41) 0.872 Charlson Index 0.97 (0.67-1.41) 0.872 Q 1040 9.90 (0.69-1.18) 0.457 2 2188 9.01 0.90 (0.69-1.18) 0.457 2 2188 9.01 0.91 (0.62-1.06) 0.125 3+ 4240 9.1 0.95 (0.83-1.09) 0.451 Stage 1 1.01 (0.79-1.30) 0.917		No	7809	-		0.87 (0.77-0.98)	0.025
No 8692 0.90 (0.80-1.01) 0.075 Age Group 65-69 0.00 0.86 (0.66-1.11) 0.253 70-74 2553 0.89 (0.71-1.11) 0.294 75-79 2425 1.14 (0.93-1.41) 0.199 80+ 2966 0.81 (0.67-0.98) 0.032 Sex 1.14 (0.93-1.41) 0.199 Race/Ethnicity 0.94 (0.81-1.10) 0.429 NH White 7273 0.86 (0.75-0.98) 0.019 NH Black 1205 0.97 (0.67-1.41) 0.872 Hispanic 744 0.97 (0.67-1.41) 0.872 Others 722 0.97 (0.67-1.41) 0.872 Charlson Index 0 1.79 (0.94-3.42) 0.078 1 2476 0.95 (0.83-1.09) 0.451 2 2188 0.91 0.95 (0.83-1.09) 0.451 3+ 4240 0.95 (0.83-1.09) 0.917 1.81 (0.94-3.49) 0.075 1 244 1.01 (0.79-1.30) 0.917 1.81 (0.94-3.49) 0.075 3+ 4240 9.95 (0.83-1.09) 0.451 0.86		Radiotherapy				Providence - Contraction - Contraction	
Age Group 65-69 2000 0.86 (0.66-1.11) 0.253 70-74 2553 0.89 (0.71-1.11) 0.294 75-79 2425 1.14 (0.93-1.41) 0.199 80+ 2966 0.81 (0.67-0.98) 0.032 Sex 0.81 (0.67-0.98) 0.032 Race/Ethnicity 0.94 (0.81-1.10) 0.429 NH White 7273 0.86 (0.75-0.98) 0.019 NH White 7273 0.90 (0.64-1.26) 0.525 Hispanic 744 1.47 (1.08-1.98) 0.014 Others 722 0.97 (0.67-1.41) 0.872 Charlson Index 0 1.47 (1.08-1.98) 0.014 Others 722 0.97 (0.67-1.41) 0.872 Stage 1 2476 0.90 (0.64-1.26) 0.125 3+ 4240 1.79 (0.94-3.42) 0.078 1 2476 0.90 (0.69-1.18) 0.457 2 2188 0.90 (0.69-1.18) 0.457 3+ 4240 1.79 (0.94-3.42) 0.075 3+ 4240 1.79 (0.97-1.30) 0.917 </td <td></td> <td>Yes</td> <td></td> <td>⊢_</td> <td></td> <td>1.22 (0.88-1.69)</td> <td>0.228</td>		Yes		⊢ _		1.22 (0.88-1.69)	0.228
Age Group 65-69 2000 0.86 (0.66-1.11) 0.253 70-74 253 1.14 (0.32-1.41) 0.199 80+ 2966 0.81 (0.67-0.98) 0.032 Sex 0.81 (0.67-0.98) 0.032 Race/Ethnicity 0.94 (0.81-1.10) 0.429 NH White 7273 0.86 (0.75-0.98) 0.019 NH White 7273 0.86 (0.75-0.98) 0.019 NH White 7273 0.90 (0.64-1.26) 0.525 Hispanic 744 0.97 (0.67-1.41) 0.872 O 1040 1.47 (1.08-1.98) 0.014 Others 722 0.97 (0.67-1.41) 0.872 Charlson Index 0 1.79 (0.94-3.42) 0.078 1 2476 1.79 (0.94-3.42) 0.078 2 2188 0.99 (0.69-1.18) 0.457 2 2188 0.81 (0.62-1.06) 0.125 3+ 4240 1.01 (0.79-1.30) 0.917 1 2446 1.81 (0.94-3.49) 0.075 1 2440 1.81 (0.94-3.49) 0.075 3+		No	8692	· •		0.90 (0.80-1.01)	0.075
70-74 2553 0.89 (0.71-1.11) 0.294 75-79 2425 1.14 (0.93-1.41) 0.199 80+ 2966 0.81 (0.67-0.98) 0.032 Sex Male 4775 0.91 (0.78-1.06) 0.219 Female 5169 0.94 (0.81-1.10) 0.429 Race/Ethnicity NH White 7273 0.90 (0.64-1.26) 0.525 Hispanic 744 0.97 (0.67-1.41) 0.872 Charlson Index 0 0.97 (0.67-1.41) 0.872 0 1040 1.79 (0.94-3.42) 0.078 1 2476 0.90 (0.69-1.18) 0.457 2 2188 0.81 (0.62-1.06) 0.125 3+ 4240 0.95 (0.83-1.09) 0.451 Stage 1 2476 0.95 (0.83-1.09) 0.451 II 2424 0.95 (0.83-1.09) 0.917 0.917 II 2429 0.97 (0.74-1.22) 0.801 0.95 (0.83-1.09) 0.917 1 2446 0.95 (0.83-1.09) 0.917 0.95 (0.83-1.09) 0.917 0.917 0.95 (0.83-1.09)		Age Group					
70-74 2553 +++ 0.89 (0.71-1.11) 0.294 75-79 2425 +++ 1.14 (0.93-1.41) 0.199 80+ 2966 -++ 0.81 (0.67-0.98) 0.032 Sex + 0.91 (0.78-1.06) 0.219 Female 5169 +++ 0.94 (0.81-1.10) 0.429 Race/Ethnicity + 0.90 (0.64-1.26) 0.525 Hispanic 744 + 0.90 (0.64-1.26) 0.525 Hispanic 744 0.97 (0.67-1.41) 0.872 O 1040 1.47 (1.08-1.98) 0.014 Others 722 0.97 (0.67-1.41) 0.872 Charlson Index 0.97 (0.67-1.41) 0.872 0 1040 1.79 (0.94-3.42) 0.078 1 2476 0.90 (0.69-1.18) 0.457 2 2188 0.90 (0.69-1.18) 0.457 3+ 4240 0.95 (0.83-1.09) 0.917 II 2446 0.95 (0.83-1.09) 0.951<		65-69	2000	H H -1		0.86 (0.66-1.11)	0.253
75-79 2425 1.14 (0.93-1.41) 0.199 80+ 2966 0.81 (0.67-0.98) 0.032 Sex		70-74	2553	H H -1		,	
80+ 2966 0.81 (0.67-0.98) 0.032 Sex Male 4775 0.91 (0.78-1.06) 0.219 Female 5169 0.94 (0.81-1.10) 0.429 Race/Ethnicity 0.94 (0.81-1.10) 0.429 NH White 7273 0.90 (0.64-1.26) 0.525 Hispanic 744 0.97 (0.67-1.41) 0.872 Others 722 1.47 (1.08-1.98) 0.014 Others 722 1.47 (1.08-1.98) 0.014 Others 722 1.47 (1.08-1.98) 0.816 (0.67-0.41) 0.872 Charlson Index 0.97 (0.67-1.41) 0.872 0.97 (0.67-1.41) 0.872 1 2476 1.79 (0.94-3.42) 0.078 0.95 (0.83-1.08) 0.457 2 2188 1.79 (0.94-3.42) 0.075 0.81 (0.62-1.06) 0.125 3+ 4240 1.41 0.95 (0.83-1.09) 0.451 Stage 1 1.91 (0.79-1.30) 0.917 I 381 97 (0.78-1.22) 0.801 III 2429 94 0.86 (0.74-1.01) 0.86 (0.74-1.01) <td></td> <td>75-79</td> <td>2425</td> <td>F-</td> <td></td> <td></td> <td></td>		75-79	2425	F-			
Sex Male 4775 H 0.91 (0.78-1.06) 0.219 Female 5169 H 0.94 (0.81-1.10) 0.429 Race/Ethnicity NH White 7273 0.86 (0.75-0.98) 0.019 NH Black 1205 0.90 (0.64+1.26) 0.525 Hispanic 744 1.47 (1.08-1.98) 0.014 Others 722 0.97 (0.67-1.41) 0.872 Charlson Index 0 1.79 (0.94-3.42) 0.078 1 2476 0.90 (0.69-1.18) 0.457 2 2188 0.90 (0.69-1.18) 0.457 3+ 4240 H 0.95 (0.83-1.09) 0.451 Stage 1 1.01 (0.79-1.30) 0.917 II 381 0.97 (0.78-1.22) 0.801 IV 4053 0.86 (0.74-1.01) 0.069		80+	2966	H			
Female 5169 0.031 (0.10 1.050) 0.429 Race/Ethnicity 0.94 (0.81-1.10) 0.429 NH White 7273 0.94 (0.81-1.10) 0.429 NH Black 1205 0.90 (0.64-1.26) 0.525 Hispanic 744 1.47 (1.08-1.98) 0.014 Others 722 0.97 (0.67-1.41) 0.872 Charlson Index 1.79 (0.94-3.42) 0.078 1 2476 0.90 (0.69-1.18) 0.457 2 2188 0.81 (0.62-1.06) 0.125 3+ 4240 1.01 (0.79-1.30) 0.917 II 381 1.81 (0.94-3.49) 0.075 III 2244 1.81 (0.94-3.49) 0.075 IV 4053 0.86 (0.74-1.01) 0.86 (0.74-1.01)		Sex					01002
Female 5169 0.94 (0.81-1.10) 0.429 Race/Ethnicity NH White 7273 0.86 (0.75-0.98) 0.019 NH Black 1205 0.90 (0.64-1.26) 0.525 Hispanic 744 1.47 (1.08-1.98) 0.014 Others 722 0.97 (0.67-1.41) 0.872 Charlson Index 0 1.47 (1.08-1.98) 0.014 0 1040 1.79 (0.94-3.42) 0.078 1 2476 0.90 (0.69-1.18) 0.457 2 2188 0.81 (0.62-1.06) 0.125 3+ 4240 1.4 0.95 (0.83-1.09) 0.451 Stage 1 1.01 (0.79-1.30) 0.917 II 381 1.81 (0.94-3.49) 0.075 III 2429 1.81 (0.94-3.49) 0.075 IV 4053 1.81 0.86 (0.74-1.01) 0.069		Male	4775	H		0.91 (0.78-1.06)	0 219
Race/Ethnicity 0.86 (0.75-0.98) 0.019 NH White 7273 0.90 (0.64-1.26) 0.525 Hispanic 744 1.47 (1.08-1.98) 0.014 Others 722 0.97 (0.67-1.41) 0.872 Charlson Index 0 1040 1.79 (0.94-3.42) 0.078 1 2476 0.90 (0.69-1.18) 0.457 2 2188 0.81 (0.62-1.06) 0.125 3+ 4240 1.41 0.95 (0.83-1.09) 0.451 Stage I 2244 1.81 (0.94-3.49) 0.075 II 381 1.81 (0.94-3.49) 0.075 IV 4053 9.453 0.86 (0.74-1.01) 0.069		Female	5169	HEH.			
NH White 7273 0.86 (0.75-0.98) 0.019 NH Black 1205 0.90 (0.64-1.26) 0.525 Hispanic 744 1.47 (1.08-1.98) 0.014 Others 722 0.97 (0.67-1.41) 0.872 Charlson Index 0 1.79 (0.94-3.42) 0.078 0 1040 1.79 (0.94-3.42) 0.078 1 2476 0.90 (0.69-1.18) 0.457 2 2188 0.81 (0.62-1.06) 0.125 3+ 4240 1.41 0.95 (0.83-1.09) 0.451 Stage 1 1.01 (0.79-1.30) 0.917 II 381 1.81 (0.94-3.49) 0.075 III 2429 0.97 (0.78-1.22) 0.801 IV 4053 0.86 (0.74-1.01) 0.069		Race/Ethnicity				0.01 (0.01 1.10)	0.120
NH Black 1205 0.00 (0.64-1.26) 0.525 Hispanic 744 1.47 (1.08-1.98) 0.014 Others 722 0.97 (0.67-1.41) 0.872 Charlson Index 0 1.79 (0.94-3.42) 0.078 1 2476 0.90 (0.69-1.18) 0.457 2 2188 0.81 (0.62-1.06) 0.125 3+ 4240 1.01 (0.79-1.30) 0.917 I 381 1.81 (0.94-3.49) 0.075 III 22429 1.81 (0.94-3.49) 0.075 IV 4053 9 0.86 (0.74-1.01) 0.069			7273	-		0.86 (0.75-0.98)	0.019
Hispanic 744 1.47 (1.08-1.98) 0.014 Others 722 0.97 (0.67-1.41) 0.872 Charlson Index 1.79 (0.94-3.42) 0.078 1 2476 0.90 (0.69-1.18) 0.457 2 2188 0.81 (0.62-1.06) 0.125 3+ 4240 1.01 (0.79-1.30) 0.917 II 381 1.81 (0.94-3.49) 0.075 III 2244 1.01 (0.79-1.30) 0.917 II 381 0.97 (0.78-1.22) 0.801 IV 4053 0.86 (0.74-1.01) 0.069							
Others 722 Image: Charlson Index 0.97 (0.67-1.41) 0.872 0 1040 1.79 (0.94-3.42) 0.078 1 2476 0.90 (0.69-1.18) 0.457 2 2188 0.81 (0.62-1.06) 0.125 3+ 4240 0.95 (0.83-1.09) 0.451 Stage I 2244 1.01 (0.79-1.30) 0.917 II 381 1.81 (0.94-3.49) 0.075 III 2429 0.97 (0.78-1.22) 0.801 IV 4053 0.86 (0.74-1.01) 0.069							
Charlson Index 0 1040 1.79 (0.94-3.42) 0.078 1 2476 0.90 (0.69-1.18) 0.457 2 2188 0.81 (0.62-1.06) 0.125 3+ 4240 0.95 (0.83-1.09) 0.451 Stage I 2244 1.01 (0.79-1.30) 0.917 II 381 1.81 (0.94-3.49) 0.075 III 2429 0.97 (0.78-1.22) 0.801 IV 4053 0.86 (0.74-1.01) 0.069							
0 1040 1.79 (0.94-3.42) 0.078 1 2476 0.90 (0.69-1.18) 0.457 2 2188 0.81 (0.62-1.06) 0.125 3+ 4240 0.95 (0.83-1.09) 0.451 Stage I 2244 1.81 (0.94-3.49) 0.075 II 381 1.81 (0.94-3.49) 0.075 III 381 0.97 (0.78-1.22) 0.801 IV 4053 0.86 (0.74-1.01) 0.069						0.37 (0.07-1.41)	0.072
1 2476 0.90 (0.69-1.18) 0.457 2 2188 0.81 (0.62-1.06) 0.125 3+ 4240 1 0.95 (0.83-1.09) 0.451 Stage I 2244 1.01 (0.79-1.30) 0.917 II 381 1.81 (0.94-3.49) 0.075 III 2429 0.97 (0.78-1.22) 0.801 IV 4053 0.86 (0.74-1.01) 0.069			1040	H		1 70 (0 04 3 42)	0.078
2 2188 0.81 (0.62-1.06) 0.125 3+ 4240 0.95 (0.83-1.09) 0.451 Stage I 2244 1.01 (0.79-1.30) 0.917 II 381 1.81 (0.94-3.49) 0.075 III 2429 0.97 (0.78-1.22) 0.801 IV 4053 0.86 (0.74-1.01) 0.069					-		
3+ 4240 1 0.95 (0.83-1.09) 0.451 Stage 1 2244 1.01 (0.79-1.30) 0.917 II 381 1.81 (0.94-3.49) 0.075 III 2429 0.97 (0.78-1.22) 0.801 IV 4053 0.86 (0.74-1.01) 0.069							
Stage 1.01 (0.79-1.30) 0.917 II 381 1.81 (0.94-3.49) 0.075 III 2429 0.97 (0.78-1.22) 0.801 IV 4053 0.86 (0.74-1.01) 0.069				H			
I 2244 1.01 (0.79-1.30) 0.917 II 381 1.81 (0.94-3.49) 0.075 III 2429 1.81 (0.94-3.49) 0.075 IV 4053 0.86 (0.74-1.01) 0.069			1210			0.85 (0.85-1.08)	0.451
II 381 1.81 (0.94-3.49) 0.075 III 2429 1.81 (0.94-3.49) 0.075 IV 4053 0.86 (0.74-1.01) 0.069		l	2244			1 01 (0 70 1 20)	0.017
III 2429 → 0.97 (0.78-1.22) 0.801 IV 4053 → 0.86 (0.74-1.01) 0.069		, II					
IV 4053 0.86 (0.74-1.01) 0.069					-	,	
				H H -1			
Histology			031			0.87 (0.59-1.28)	0.488
			7536			0.07 (0.04.4.40)	0.000
0.07 (0.04 1.10) 0.000				H I			
Non-Small Cell 1353 1.00 (0.89-1.13) 0.982		Non-Sman Cell	1303	· ••• '		1.00 (0.89-1.13)	0.982

0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0

← Favours DDP4 inhibitors Favours refernce group→

While the role of metformin is well-established, it was interesting to find that the combined use of DPP4 inhibitors with metformin had a lower HR as compared to metformin or DPP4 inhibitors alone (Figure 5). These findings are consistent in our analysis in a combined cohort of CRC and lung cancer as well as independent cohorts of CRC or lung cancer. Although there is no direct comparison, the comparative improvement of HR for a combination of DPP4 inhibitors and metformin as compared to either drug alone is encouraging and suggests an additive effect on OS of the combination. This finding was also noticed in the in-vivo study by Pereira et al.¹⁰ Our study is based on SEER-Medicare data until 2013 prior to the use of immunotherapy drugs for cancer treatment. It will be interesting to see how DPP4 inhibitors interplay with immunotherapy drugs as suggested by Barreira da Silva et al.⁹

As we mentioned before, various preclinical or in-vivo studies have shown the role of DPP4/CD26 in either suppressing or activating tumor cells. We believe that DPP4/ CD26 exerts its effects on tumor cells by interacting with immune cells through chemokines, but exact mechanisms are still unknown. Immune response against tumor cells depends on the infiltration of the tumor microenvironment by T cells, which in turn is guided by chemokines. DPP4/ CD26 cleaves dipeptides from certain chemokines leading to their degradation, which limits infiltration of effector T cell into solid tumors. Thus, inhibition of DPP4 enzymatic activity by DPP4 inhibitors would limit degradation of chemokines, enhance tumor infiltration by T cells, and tumor cell killing.

4.1 **Study limitations**

SEER database includes data from 19 different geographical areas covering approximately 34% of the US population. Although this dataset includes patient population from diverse demographics and locations, it still does not include the entire US population.²⁰ Therefore, both data and results might be affected by various local risk factors, including access to health care, and caution should be exerted before generalization.²¹ Also, this study is retrospective in nature that carries limitations of a retrospective study and prevent us from drawing direct causal inferences regarding the use of DPP4 inhibitors and survival outcomes. Moreover, our hypothesis of the underlying mechanism of action by enhanced immune response is applicable to any cancer or histologic type. The




FIGURE 5 This shows the multivariable analysis of combined cohort, CRC, and lung cancer patients. CRC, colorectal cancer

sample size was another significant limitation, and we believe larger sample size would have consolidated the positive trends noted in this study to statistically significant findings.

CONCLUSION 5

3926

This SEER-Medicare study further establishes the role of DPP4 inhibitors as cancer inhibitory, especially in combination with metformin. We plan to follow these findings with prospective trials.

ACKNOWLEDGMENT

We acknowledge that the study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The

authors acknowledge the efforts of the Applied Research Program, National Cancer Institute; the Office of Research, Development and Information, Centers for Medicare & Medicaid Services; Information Management Services (IMS), Incorporated; and the SEER Program registries in the creation of the SEER-Medicare database. This manuscript has been approved by IMS as compliant with the database user agreement.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

AUTHOR CONTRIBUTIONS

Long H. Dang, Nam H. Dang, Chintan Shah, Jinhai Huo, and Rohit Bishnoi designed the study. Jinhai Huo, Nam H.

Cancer Medicine

Dang, and Long H. Dang are principal investigators and mentor authors with equal contribution. Rohit Bishnoi and Young-Rock Hong were major contributor in writing manuscript. Long H. Dang, Nam H. Dang, Chintan Shah, Jinhai Huo, Azka Ali, and William Paul Skelton IV contributed in drafting, editing, and revising the manuscript. Jinhai Huo and Young-Rock Hong provided statistical analysis. All authors read and approved the final manuscript.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The Institution Review Board (IRB) at the University of Florida, Gainesville FL, approved this study and all standard ethical guidelines were followed. Full waiver of informed consent was obtained.

CONSENT TO PUBLICATION

Not applicable. The manuscript does not contain any individual's data.

DATA AVAILABILITY STATEMENT

The datasets and study analysis details are available from the corresponding author on reasonable request.

ORCID

Rohit Bishnoi D https://orcid.org/0000-0001-5976-3510 Young-Rock Hong D https://orcid.org/0000-0002-0366-5687 Jinhai Huo D https://orcid.org/0000-0002-5477-9756

REFERENCES

- Havre P, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang N. The role of CD26/dipeptidyl peptidase IV in cancer. *Front Biosci.* 2008;13:1634-1645.
- Pro B, Dang N. CD26/dipeptidyl peptidase IV and its role in cancer. *Histol Histopathol*. 2004;19(4):1345-1351.
- Beckenkamp A, Davies S, Willig J, Buffon A. DPPIV/CD26: a tumor suppressor or a marker of malignancy? *Tumor Biol*. 2016;37(6):7059-7073.
- Liang P-I, Yeh B-W, Li W-M, et al. DPP4/CD26 overexpression in urothelial carcinoma confers an independent prognostic impact and correlates with intrinsic biological aggressiveness. *Oncotarget*. 2017;8(2):2995-3008.
- Lee J-J, Wang T-Y, Liu C-L, et al. Dipeptidyl peptidase IV as a prognostic marker and therapeutic target in papillary thyroid carcinoma. *J Clin Endocrinol Metab.* 2017;102(8):2930-2940.
- Larrinaga G, Perez I, Sanz B, et al. Dipeptidyl-peptidase IV activity is correlated with colorectal cancer prognosis. *PLoS ONE*. 2015;10(3):e0119436.

- Ho L, Aytac U, Stephens LC, et al. In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. *Clin Cancer Res.* 2001;7(7):2031-2040.
- Angevin E, Isambert N, Trillet-Lenoir V, et al. First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers. *Br J Cancer*. 2017;116(9):1126-1134.
- Barreira da Silva R, Laird ME, Yatim N, et al. inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. *Nat Immunol.* 2015;16(8):850–858.
- Pereira FV, Melo A, Low JS, et al. Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. *Oncotarget*. 2018;9(40):25808-25825.
- Wang H, Liu X, Long M, et al. NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. *Sci Transl Med.* 2016;8(334):334ra51.
- Ali A, Fuentes A, Skelton W IV, et al. A multi-center retrospective analysis of the effect of DPP4 inhibitors on progression-free survival in advanced airway and colorectal cancers. *Mol Clin Oncol.* 2018;10(1):118-124.
- https://healthcaredelivery.cancer.gov/seermedicare/aboutdata/ program.html. Accessed May 2, 2019.
- Charlson ME, Sax FL, MacKenzie CR, Fields SD, Braham RL, Douglas RG Jr. Assessing illness severity: does clinical judgment work? *J Chronic Dis.* 1986;39(6):439-452.
- Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. *J Clin Epidemiol*. 2000;53(12):1258-1267.
- Mei Z-B, Zhang Z-J, Liu C-Y, et al. Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. *PLoS ONE*. 2014;9(3):e91818.
- Meng F, Song L, Wang W. Metformin improves overall survival of colorectal cancer patients with diabetes: a meta-analysis. *J Diabetes Res.* 2017;2017:5063239.
- Bishnoi R, Shah C, Schmit JM, Huo JS. Metformin and stage IV colorectal cancer in elderly. J Clin Oncol. 2018;36(15_suppl):e15636-e15636.
- Zhong S, Wu Y, Yan X, Tang J, Zhao J. Metformin use and survival of lung cancer patients: Meta-analysis findings. *Indian J Cancer*. 2017;54(1):63-67.
- 20. https://seer.cancer.gov/about/factsheets/SEER_Overview.pdf. Accessed May 2, 2019.
- Kuo TM, Mobley LR. How generalizable are the SEER registries to the cancer populations of the USA? *Cancer Causes Control*. 2016;27(9):1117-1126.

How to cite this article: Bishnoi R, Hong Y-R, Shah C, et al. Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study. *Cancer Med.* 2019;8:3918–3927. https://doi.org/10.1002/cam4.2278

-WILEY